Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.53 |
| ▸ | MMP12 | P39900 | 1/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 5/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 5/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | KMO | O15229 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3942843 | 0.89 | PRKCA (0.51) | PRKCAMMP12NR1I2SCN9ACYP3A4 | |
| SCHEMBL13940166 | 0.87 | PRKCA (0.49) | PRKCAMMP12NR1I2SCN9ACHRNA7 | |
| SCHEMBL3945379 | 0.86 | PRKCA (0.49) | PRKCAMMP12NR1I2SCN9AMTNR1A | |
| SCHEMBL13940397 | 0.86 | NR1I2 (0.56) | PRKCAMMP12NR1I2SCN9ACYP3A4 | |
| SCHEMBL5476043 | 0.86 | PRKCA (0.50) | PRKCAMMP12NR1I2CYP3A4CYP2C9 | |
| SCHEMBL13940189 | 0.86 | PRKCA (0.48) | PRKCAMMP12NR1I2SCN9A | |
| SCHEMBL13940155 | 0.86 | PRKCA (0.48) | PRKCAMMP12NR1I2SCN9A | |
| SCHEMBL4020494 | 0.86 | PRKCA (0.48) | PRKCAMMP12NR1I2SCN9A | |
| SCHEMBL4830061 | 0.85 | PRKCA (0.55) | PRKCAMMP12NR1I2SCN9ACYP3A4 | |
| SCHEMBL3567697 | 0.85 | PRKCA (0.60) | PRKCAMMP12NR1I2SCN9ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348425-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| US-20060166964-A1 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166964-A1 | Inhibitors of HCV replication | EIF2AK2, HCCS, IDO1 | PRKCA 3479/4885MMP12 3512/4885NR1I2 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.